Compare KBDC & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KBDC | CSTL |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2019 |
| Metric | KBDC | CSTL |
|---|---|---|
| Price | $14.52 | $41.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $15.80 | ★ $46.00 |
| AVG Volume (30 Days) | 319.3K | ★ 323.5K |
| Earning Date | 03-02-2026 | 02-26-2026 |
| Dividend Yield | ★ 13.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $343,530,000.00 |
| Revenue This Year | $193.84 | $2.54 |
| Revenue Next Year | $9.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.15 |
| 52 Week Low | $13.06 | $14.59 |
| 52 Week High | $17.99 | $43.01 |
| Indicator | KBDC | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 44.99 | 66.08 |
| Support Level | $14.47 | $39.74 |
| Resistance Level | $14.93 | $43.01 |
| Average True Range (ATR) | 0.36 | 1.72 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 36.74 | 80.68 |
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.